^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HER-2 negative + HR negative

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Associations
7d
Outcomes of Pregnancy-Associated Breast Cancer: A Tertiary Care Cancer Hospital Experience. (PubMed, Cureus)
Trastuzumab, tamoxifen, and radiotherapy were administered post-delivery. Conclusion Future research should improve PABC patient outcomes by improving diagnostic methods, refining treatment protocols, investigating long-term effects, developing early detection tools, tailoring treatment plans, and evaluating treatment impact on fetal health. It is essential to establish guidelines for mother and child safety and address emotional and psychological needs.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 negative + HR negative
|
Herceptin (trastuzumab) • tamoxifen
17d
The impact of the new Histological classification of breast cancer with the introduction of Her 2 low status. (PubMed, J Gynecol Obstet Hum Reprod)
Our study highlights differences in age and hormonal receptor status among HER2 status groups. The introduction of HER2-low classification opens the door to new treatment strategies, especially with antibody-drug combinations that use HER2 receptors to deliver drugs. Although significant differences in survival rates were not found, ongoing research is crucial to understand how this new classification affects patient parameters. Additionally, it is essential to consider individual factors like age and hormone receptor status when deciding on the best treatment approach.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 negative + HR negative
19d
First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis. (PubMed, Medicine (Baltimore))
When it is necessary to consider the accessibility of antibody-drug conjugates and the economics of patients, carboplatin-based chemotherapy may be provided to HER2-low patients as a more convenient, cost-effective and efficient option on the front line. Forecasting the efficacy and prognosis via inflammatory index such as NLR before the commencement of the treatment could enhance the precision and efficiency of carboplatin-based regimens.
Observational data • Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 expression • HER-2 negative + HR negative
|
carboplatin
25d
Investigating HER2-Low in Early Breast Cancer: Prognostic Implications and Age-Related Prognostic Stratification. (PubMed, Cancer Med)
This extensive retrospective study demonstrates that HER2-low status cannot serve as an independent prognostic factor in the entire cohort, nor in the HR-positive and HR-negative groups individually. However, the combined factors of HER2-low status and age may indicate a potential contribution to the prognostic stratification of TNBC.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 negative + HR negative
1m
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression. (PubMed, Breast Cancer)
In the group of patients who underwent mastectomy (n = 54,476), 6226 (11.4%) received radiation therapy to the chest wall. Of the 13,950 patients receiving preoperative chemotherapy with or without molecular targeted therapy, 4308 (30.9%) achieved a pathological complete response, with the highest rate of 60.5% in patients with the hormone receptor-negative/HER2-positive subtype.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • HER-2 negative + HR negative
1m
Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010-2019. (PubMed, Cancer)
In this large, population-based study of patients with stage IA HER2-positive breast cancer, patients who had tumors ≤1 cm had excellent outcomes with or without chemotherapy. Patients with pT1c tumors had a greater increase in BCSS with the receipt chemotherapy.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • EGFR positive • HER-2 negative + HR negative
3ms
Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET/CT imaging. (PubMed, Cancer Imaging)
Our study demonstrated the HR-positive HER2-low breast cancer exhibited a particularity in glucose metabolic profile. Additionally, HER2-zero patients with elevated metabolism were associated with inferior prognosis and warranted careful attention in clinical evaluations.
Clinical • Retrospective data • Journal • FDG PET
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 negative + HR negative • HER-2 positive + HR negative
3ms
Breast biomarkers evolution between primary and distant metastasis: incidence and significance. (PubMed, Histopathology)
Five-profile classification provides a more accurate idea about the rate of potential change in treating BC in the metastatic setting.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative • HER-2 positive + HR negative
3ms
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials. (PubMed, Front Endocrinol (Lausanne))
With the approval of trastuzumab deruxtecan for the treatment of unresectable/metastatic HER2-low breast cancer, human epidermal growth factor receptor 2 (HER2)-low has emerged as a clinically actionable biomarker...Patients with discordant HER2 status had better responses to platinum-based chemotherapy. Therefore, for patients with HER2-0 primary lesions, re-evaluation of HER2 status in metastatic lesions through biopsy may offer new treatment opportunities.
Retrospective data • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 negative + HR negative
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
3ms
Targeted and cytotoxic inhibitors used in the treatment of breast cancer. (PubMed, Pharmacol Res)
Hormonal or endocrine therapy includes selective estrogen receptor modulators (SERMs) such as raloxifene, tamoxifen and toremifene, selective estrogen-receptor degraders (SERDs) including elacestrant and fulvestrant, and aromatase inhibitors such as anastrozole, letrozole, and exemestane...These agents include taxanes (docetaxel, nab-paclitaxel, and paclitaxel), anthracyclines (doxorubicin, epirubicin), anti-metabolites (capecitabine, gemcitabine, fluorouracil, methotrexate), alkylating agents (carboplatin, cisplatin, and cyclophosphamide), and drugs that target microtubules (eribulin, ixabepilone, ado-trastuzumab emtansine). Patients with ER-positive tumors are treated with 5-10 years of endocrine therapy and chemotherapy. For patients with metastatic breast cancer, standard first-line and follow-up therapy options include targeted approaches such as CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PDL1 immunotherapy, depending on the tumor type and molecular profile.
Review • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative • HER-2 positive + HR negative
|
cisplatin • carboplatin • gemcitabine • docetaxel • 5-fluorouracil • tamoxifen • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • capecitabine • albumin-bound paclitaxel • cyclophosphamide • fulvestrant • Halaven (eribulin mesylate) • methotrexate • letrozole • epirubicin • anastrozole • exemestane • Orserdu (elacestrant) • Ixempra (ixabepilone) • raloxifene hydrochloride
3ms
Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))
In both hormone receptor (HR)-positive (Log rank test, P=0.052) and HR-negative (Log rank test, P=0.125) subgroups, HER2 2+/FISH-negativity showed a marginally significant adverse influence on DFS. In older patients with HER2-negative/high-risk breast cancer undergoing standard adjuvant chemotherapy, our findings suggest that HER2 2+/FISH-negativity has an independent negative impact on prognosis.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification • HER-2 negative • HER-2 negative + HR negative
4ms
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PGR expression • HER-2 negative + HR negative
|
BNT326
4ms
Trial completion
|
HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
4ms
Combination therapy • Trial primary completion date • BRCA Companion diagnostic • PARP Companion diagnostic • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
|
PD-L1 IHC 22C3 pharmDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
carboplatin • gemcitabine • nadunolimab (CAN04)
4ms
Clinical and financial impact of implementation of Oncotype Dx in women with HR positive HER2 negative early breast cancer treated in a Chilean Cancer Center. (SABCS 2024)
With respect to the financial analysis, and taking into account the costs in both groups, the savings are marginal. Although more data are still required, in this study, the results suggest that Oncotype Dx should be indicated in N1 and only in N0 patients with Predict less than 4 and tumor grade 1 and 2, optimizing resources and improving cost-effectiveness.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR negative
|
Oncotype DX Breast Recurrence Score®Test
4ms
Development & Validation of RSC4All: an Artificial Intelligence-driven Machine Learning Nomogram Enhanced with Synthetic Data to Predict RSClin® Results & Guide Adjuvant Treatment of Node-negative HR-positive/HER2-negative Early Breast Cancer (SABCS 2024)
RSC4All accurately reproduces RSClinâ„¢ results to support treatment decisions for patients with N0 HR+/HER2- eBC. The incorporation of SD further enhanced the predictive accuracy of the ML tool, supporting the value of AI-driven data augmentation in oncology.
Clinical • Machine learning
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • EGFR negative • HR positive + HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative
|
Oncotype DX Breast Recurrence Score®Test
4ms
Screening of BindingDB database ligands against EGFR, HER2, Estrogen, Progesterone and NF-κB receptors based on machine learning and molecular docking. (PubMed, Comput Biol Med)
The binding energy range for these ligands against their respective targets was calculated to be between -15 and -5 kcal/mol. Finally, based on general and common rules in medicinal chemistry, we selected 2, 3, 3, and 8 new ligands with high priority for further studies in the EGFR+HER2, ER, NF-κB, and PR classes, respectively.
Journal • Machine learning
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • HR positive + HER-2 positive • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative • HR negative + HER-2 positive
5ms
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 negative + HR negative
5ms
Combination therapy • Trial primary completion date • BRCA Companion diagnostic • PARP Companion diagnostic • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
|
PD-L1 IHC 22C3 pharmDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
carboplatin • gemcitabine • nadunolimab (CAN04)
5ms
Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study. (PubMed, BMC Cancer)
This study reveals the high heterogeneity of HER2-positive breast cancer related to HR status in clinicopathological features, metastasis patterns, and outcomes. Large randomized controlled trials are warranted to optimize treatment strategies for the HER2-positive breast cancer population.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • EGFR positive • HER-2 negative + HR negative • HER-2 positive + HR negative
5ms
ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov)
P2, N=252, Recruiting, Guangdong Provincial People's Hospital | Initiation date: Jan 2024 --> Sep 2024
Trial initiation date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • ER positive + PGR positive • HER-2 negative + ER positive • HER-2 negative + HR negative
|
carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)
6ms
Arise-FJ-B02: Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=29, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting | N=20 --> 29 | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Dec 2024
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 expression • HER-2 negative + HR negative
|
AiTan (rivoceranib) • albumin-bound paclitaxel
6ms
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis. (PubMed, J Clin Oncol)
These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.
Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative
6ms
IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
P1/2, N=29, Recruiting, University of Florida | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative • HR negative + HER-2 positive
|
Tecentriq (atezolizumab) • Fotivda (tivozanib)
6ms
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. (PubMed, Nat Med)
I-SPY2.2 uses a sequential multiple assignment randomization trial design that includes three sequential blocks of biologically targeted neoadjuvant treatment: the experimental agent(s) (block A), a taxane-based regimen tailored to the tumor subtype (block B) and doxorubicin-cyclophosphamide (block C). Dato-DXd was particularly active in the hormone receptor-negative/HER2-Immune-DNA repair deficiency- signature, warranting further investigation, and was safe in other subtypes in patients who followed the treatment strategy. ClinicalTrials.gov registration: NCT01042379 .
P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • DRD (DNA Repair Deficiency)
|
HER-2 negative • DDR • HR negative • DRD • HER-2 negative + HR negative
|
doxorubicin hydrochloride • cyclophosphamide • Datroway (datopotamab deruxtecan)
6ms
Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy. (PubMed, Am J Cancer Res)
HER-2 zero to low conversion was associated with better DFS in patients who are HER-2 zero. These results provide a valuable reference for the potential application of anti-HER-2 ADC in an adjuvant setting for patients with residual disease after NAC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative • HER-2 amplification + HR-positive • HER-2 negative + HR negative
6ms
HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome. (PubMed, Eur J Cancer)
Among females with LFS and BC, HER2-positive subtype was associated with younger age at diagnosis and a predominant HR-positivity. Favorable pCR rates were observed among those receiving neoadjuvant HER2-directed therapies, for both HR-positive and negative tumors. These data may inform the counseling and care of patients with LFS.
Journal
|
TP53 (Tumor protein P53)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 negative + HR negative • HER-2 positive + HR negative
|
Herceptin (trastuzumab)
6ms
Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis. (PubMed, Front Immunol)
The analysis revealed that the six most effective neoadjuvant treatment regimens for HR+/HER2- breast cancer were: CT(A)+olaparib (82.5%), CT(A)+nivolumab (76.5%), Com (74.9%), CT (72.1%), Mono+eribulin (72.0%), and CT(A)+pembrolizumab (70.4%).Paired meta-analysis for pathological complete response (pCR) found no statistically significant distinction between treatment regimens that included both anthracycline and immunosuppressants and regimens that relied solely on anthracycline chemotherapy(OR:1.14, 95%ci 0.79-1.64, I2 = 71%, P=0.50). Although pCR is valuable in assessing the effect of neoadjuvant therapy in some cases, prognostic prediction and efficacy assessment in patients with HR+/HER2- breast cancer should be based on a combination of broader clinical and biological characteristics. PROSPERO https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024534539, CRD42024501740.
Clinical • Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Halaven (eribulin mesylate)
6ms
Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. (PubMed, Ann Surg Oncol)
Over 90% of patients with clinically node-negative, microinvasive and T1a breast cancer remain pathologically node-negative following axillary staging. However, higher rates of nodal disease were found among Black patients, older patients, and patients with lobular cancer and significant comorbidities.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR negative • EGFR positive • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative